Not yet recruiting NCT07555301
Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: sparsentan, sparsentan.
- Who it may be relevant to
- Registry conditions: IgA Nephropathy (IgAN). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Switzerland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
An observational study tracking the clinical course of patients with IgA nephropathy.
Detailed description
The aim is to monitor the clinical progression of patients with histologically confirmed IgA nephropathy in terms of GFR and proteinuria.
Interventions
- Drug sparsentan
Follow up observation of patients with IgA Nephropathy on sparsentan regarding Albuminuria and GFR - Drug sparsentan
follow up observation of Albuminuria and GFR in IgA patients in therapy with sparsentan
Primary outcome measures
- Change of Albuminuria [Time frame: 36 months]
Eligibility criteria
Inclusion criteria
- IgA Nephropathy, Use of Sparsentan
Exclusion criteria
- age < 18y
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Switzerland · 1 center
- Stadtspital Zurich — Zurich
Identifiers
NCT: NCT07555301 · WaidCH2026